Regeneron seeks to edge Roche out of DME space

Share this article:
Eylea outduels Lucentis for physician mindshare, survey shows
Eylea outduels Lucentis for physician mindshare, survey shows

A year after its eye drug Lucentis landed the FDA's approval for diabetic macular edema, Roche's hold on this Eylea-free zone of the market may soon be ending. Regeneron, Eylea's manufacturer, said Tuesday that it expects to submit an NDA for this very same indication to the FDA this year, while its European marketing partner, Bayer, is on track to do the same abroad.

This would mean more than a me-too in the diabetic macular edema (DME) space. As noted by Forbes, Lucentis has a downside in that its label has a fatality warning. Eylea's does not, and that could give the Regeneron drug an edge if it too gets approved for use in DME.

It's not the first threat to Lucentis' hold on the eye market. The wet macular-degeneration drug saw immediate competition from off-label use of Genentech's Avastin, then from macular-degeneration newcomer Eylea.

DME is linked to blurry vision and even blindness, and estimates say it affects about 560,000 Americans.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.